Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And GlaukosBenzinga • 12/02/24
New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral ApproachesPRNewsWire • 11/18/24
Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion GloballyPRNewsWire • 11/12/24
New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation TherapyPRNewsWire • 10/29/24
Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024PRNewsWire • 10/10/24
NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI PlatformZacks Investment Research • 09/25/24
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord StimulationPRNewsWire • 09/24/24
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024PRNewsWire • 07/09/24